ID   FM55M2
AC   CVCL_C590
SY   FM-55-M2; FM 55 M2; FM55II
DR   cancercelllines; CVCL_C590
DR   Cosmic; 808540
DR   Cosmic; 972266
DR   Cosmic; 1006225
DR   Cosmic; 1047666
DR   Cosmic; 2163768
DR   ECACC; 13012559
DR   ESTDAB; ESTDAB-013
DR   GEO; GSM156043
DR   IARC_TP53; 26093
DR   Progenetix; CVCL_C590
DR   Wikidata; Q54835047
RX   PubMed=7656272;
RX   PubMed=8665567;
RX   PubMed=8968104;
RX   PubMed=11225993;
RX   PubMed=15592718;
RX   PubMed=17260012;
RX   PubMed=23851445;
CC   HLA typing: A*01,02; B*15,28; C*03 (PubMed=7656272).
CC   HLA typing: A*01:01,02:01; B*08:01,15:01:01:01; C*07:01:01,03:04; DPB1*04:01,13:01; DQB1*03:02,03:01:01; DRB1*11:01,04:01 (PubMed=15592718).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Leu199Ter (c.596T>A); ClinVar=VCV000376329; Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg455Ter (c.1363C>T); ClinVar=VCV000126837; Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445).
CC   Omics: Array-based CGH.
CC   Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072.
ST   Source(s): ECACC=13012559; ESTDAB=ESTDAB-013
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 11
ST   D16S539: 12,13
ST   D3S1358: 14
ST   D5S818: 10,11
ST   D7S820: 8,10
ST   FGA: 24
ST   TH01: 5,7
ST   TPOX: 9,11
ST   vWA: 17,18
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C589 ! FM55M1
OI   CVCL_C591 ! FM55p
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 02-05-24; Version: 23
//
RX   PubMed=7656272; DOI=10.1007/BF01527402;
RA   Kirkin A.F., Petersen T.R., Olsen A.C., Li L., thor Straten P.,
RA   Zeuthen J.;
RT   "Generation of human-melanoma-specific T lymphocyte clones defining
RT   novel cytolytic targets with panels of newly established melanoma cell
RT   lines.";
RL   Cancer Immunol. Immunother. 41:71-81(1995).
//
RX   PubMed=8665567; DOI=10.1007/s002620050272;
RA   Kirkin A.F., thor Straten P., Zeuthen J.;
RT   "Differential modulation by interferon gamma of the sensitivity of
RT   human melanoma cells to cytolytic T cell clones that recognize
RT   differentiation or progression antigens.";
RL   Cancer Immunol. Immunother. 42:203-212(1996).
//
RX   PubMed=8968104;
RA   Bartkova J., Lukas J., Guldberg P., Alsner J., Kirkin A.F.,
RA   Zeuthen J., Bartek J.;
RT   "The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently
RT   altered in melanoma pathogenesis.";
RL   Cancer Res. 56:5475-5483(1996).
//
RX   PubMed=11225993; DOI=10.1007/s002620000154;
RA   Real L.M., Jimenez P., Kirkin A.F., Serrano A., Garcia A., Canton J.,
RA   Zeuthen J., Garrido F., Ruiz-Cabello Osuna F.;
RT   "Multiple mechanisms of immune evasion can coexist in melanoma tumor
RT   cell lines derived from the same patient.";
RL   Cancer Immunol. Immunother. 49:621-628(2001).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A.,
RA   Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M.,
RA   Guldberg P., Borg A.;
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//